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Abstract
Receptor endocytosis is critical for cell signaling. IGF1R mediates an autocrine loop that is de-regulated in Ewing Sarcoma
(ES) cells. Here we study the impact of IGF1R internalization, mediated by clathrin and caveolin-1 (CAV1), in ES signaling. We
used clathrin and CAV1-siRNA to interfere in clathrin- and caveolin-dependent endocytosis. Chlorpromazine (CPMZ) and
methyl-beta-cyclo-dextrin (MCD) were also used in order to inhibit clathrin- and caveolin-dependent endocytosis,
respectively. We analyzed IGF1R internalization and co-localization with clathrin and CAV1 upon ligand binding, as well as
the status of the IGF1R pathway, cellular proliferation, and the apoptosis of interfered and inhibited ES cells. We performed a
high-throughput tyrosine kinase phosphorylation assay to analyze the effects of combining the IGF1R tyrosine kinase
inhibitor AEW541 (AEW) with CPMZ or MCD on the intracellular phospho-proteome. We observed that IGF1R is internalized
upon ligand binding in ES cells and that this process is dependent on clathrin or CAV1. The blockage of receptor
internalization inhibited AKT and MAPK phosphorylation, reducing the proliferative rate of ES cells and increasing the levels
of apoptosis. Combination of AEW with CPMZ or MCD largely enhanced these effects. CAV1 and clathrin endocytosis
controls IGF1R internalization and signaling and has a profound impact on ES IGF1R-promoted survival signaling. We
propose the combination of tyrosine-kinase inhibitors with endocytosis inhibitors as a new therapeutic approach to achieve
a stronger degree of receptor inhibition in this, or other neoplasms dependent on IGF1R signaling.
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Introduction
Receptor tyrosine kinases (RTKs) are involved in countless
signaling pathways and their deregulation is involved in several
diseases, in particular in cancer. Despite extensive study of these
signaling cascades, until recently RTK internalization was
believed to determine a down-regulation of RTK activity,
ultimately leading to receptor degradation. However, increasing
evidence indicates that endocytosis modulates and also sustains
signaling transduction throughout the downstream targets of
RTKs [1,2,3]. In most cell types, RTKs mainly internalize
through clathrin-dependent internalization, converging in the
formation of clathrin-coated membrane invaginations, or clathrin-
coated pits (CCPs), in a series of highly regulated steps. Regarding
caveolin-dependent internalization, receptor stimulation with
caveolar budding leads to the formation of enclosed intracellular
vesicles called ‘‘cavicles’’ [4]. Recently, it has been reported that
the phosphorylation of CAV1 and dynamin-2 leads to caveolar
fission [5]. Depending on the cellular context, internalized RTKs
may then recycle back to the plasma membrane, recruit signaling
proteins, thereby increasing active signaling from endosomes, or
simply be degraded [1,6,7].
It has recently been reported that in lung cancer IGF1R
endocytosis is triggered by ligand binding, causing IGF1R
ubiquitination and internalization via clathrin-coated vesicles
and/or caveolae [8]. Also, using an osteosarcoma model Sehat
et al., have shown that IGF1R internalization is influenced by the
ligand concentration [9], and Romanelli et al., have demonstrated
that IGF1R internalization and recycling mediates the phosphor-
ylation of AKT in glial progenitors [10]. Moreover, IGF1R is
directly involved in the growth and survival of ES cells [11,12],
and given the relevance of RTK endocytosis in cell survival here
we study the role of clathrin and/or CAV1 in ES IGF1R signaling.
Results
IGF1R is internalized by both clathrin- and CAV1-
dependent mechanisms
In keeping with recent publications indicating that RTKs
endocytosis regulates signaling transduction, we analyzed the role
of IGF1R internalization in ES. This study was performed before
and after ligand binding (IGF1) with the aim of exploring the two
most common RTKs internalization mechanisms: clathrin- and
caveolin-dependent endocytosis.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19846We observed that under basal conditions (without IGF1
stimulation), IGF1R was present in the plasma membrane.
However, upon ligand stimulation IGF1R was internalized by
clathrin-dependent mechanisms (figure 1B) and by CAV1-
dependent mechanisms, although to a lesser extent (figure 1A).
Finally, we observed IGF1R co-localization with both clathrin and
CAV1 in the endocytic vesicles (figure1 A and B).
Moreover, since ES cells have scant cytoplasm, we were
interested in confirming IGF1R signaling there, distinguishing
this signaling from that performed by active IGF1R present in the
cell membrane. As shown in figure 2, RCM/EM confirmed our
previous results, clearly demonstrating that IGF1R was located in
the cytoplasm (figure 2A top panel) and in vesicles budding off the
cell membrane (figure 2A lower panel).
In order to confirm IGF1R internalization mediated by clathrin
and CAV1, we performed co-IP studies. The results showed that
after stimulation with IGF1, IGF1R co-precipitated with both
clathrin and CAV1 (figure 2B). Again, co-precipitation occurred
mainly with clathrin. Finally, we were able to confirm our initial
hypothesis: in ES, IGF1R is indeed internalized by clathrin- and
CAV1-dependent mechanisms.
CAV1 and clathrin interference/inhibition leads to a
blockade of IGF1R internalization
Here we tested the impact of clathrin or CAV1 interference and
inhibition on IGF1R internalization and signaling using two
different approaches: 1) specific siRNAs and 2) a drug approach,
using MCD and CPMZ. MCD is known to deplete cholesterol,
disrupting caveolae,[13] while CPMZ is able to inhibit clathrin-
heavy-chain conformations.[14]
Regarding clathrin and CAV1 interference, siRNAs effectively
reduced CAV1 and clathrin protein levels (40–65% reduction) (see
Figure S1 and figure 3A). Regarding clathrin and CAV1 inhibition
through the use of MCD and CPMZ, we observed that the
disruption of caveolae and the inhibiton of clathrin-heavy-chain
conformations led to a decrease in IGF1R internalization
(figure 3B). Overall, the interference or inhibition of endocytosis
significantly decreased IGF1R levels of internalization, even after
IGF1 stimulation, IGF1R being retained in the cell membrane.
This shows that clathrin and CAV1 are key partners in IGF1R
internalization.
CAV1 and clathrin inhibition/interference impairs the
IGF1R signaling pathway in ES cells
Several groups have shown that RTKs are frequently activated
in endosomes, and so we were interested in determining the
impact of the inhibition of clathrin and CAV1 endocytosis on
IGF1R signalling. Accordingly, we also studied the consequent
effects on cell growth and survival. In order to accomplish this, we
compared the effects of CAV1 and clathrin inhibition and
interference in 3 ES cell lines (TC71, A673 and A4573) with
different levels of sensitivity to IGF1R inhibition, the A673 cell line
being less sensitive, as reported previously by our group.[11]
Globally, we observed that inhibition with MCD and CPMZ
was slightly more efficient than interference by siRNAs in all 3 cell
lines tested. Nevertheless, both approaches led to the inhibition of
IGF1R signaling, with a reduction in AKT and MAPK
phosphorylation of more than 60% (p,0.05) (figures 2C and D
and Figure S2 and Figure S3). No changes regarding IGF1R
phosphorylation were detected. The reduction in MAPK was less
evident in the case of CAV1 inhibition. Regarding CAV1 or
clathrin inhibition (treatment with MCD and CPMZ), we detected
a clear reduction in proliferation, with a dramatic induction of
apoptosis in a dose-dependent manner. The IC50 of proliferation
was similar in all cell lines (between 10–15 mM for CPMZ and 4–
4.5 mM for MCD) (figure 4A). Similar results were obtained with
the induction of apoptosis (figure 4B, and Figure S4). Additionally,
another ES cell line quite independent of IGF1 showed higher
IC50 proliferation values, showing that CPMZ and MCD toxicity
is actually related to IGF1R endocytosis inhibition and not due to
non-specific secondary effects of these drugs (Figure S5).
Regarding the siRNA approach, we obtained around 40% of
proliferation inhibition and 40–45% of apoptosis induction
(figure 4C) for CAV1/clathrin interference at 72 hours of
treatment (figure S4 for A673 and A4573 apoptosis data).
Interestingly, both treatments mainly induced late apoptosis, few
cells undergoing necrosis.
CAV1 or clathrin inhibition improves drug-induced IGF1R
tyrosine kinase inhibition
Previous observations obtained in our own work indicated that
IGF1R signaling can be enchanced after clathrin- and/or
caveolin-dependent internalization. Accordingly we were interest-
ed in testing a new drug combination that has never been assayed
before in ES. Here we tested the effect of the combination of the
commonly used tyrosine kinase inhibitor, AEW541(AEW), with
the previously evaluated endocytosis inhibitors CPMZ and MCD
on the levels of proliferation (figure 5A and B) and the induction of
apoptosis (figure 5C).
As illustrated in the isobolograms shown in figure 5A, AEW541
in combination with MCD exerted additive effects on the cell lines
tested (figure 5A). Regarding the combination of AEW with
CPMZ, the effects were synergistic in two ES cell lines (A4573 and
TC71) (with CI between 0.73–0.86, as shown in the table of
figure 5B), and additive in the case of the A673 cell line, which is
resistant to IGF1R inhibition and consequently less dependent on
the IGF1R signaling pathway, as previously shown by our group
[11,12]. As expected, we observed a marked reduction in AKT
and ERK1/2(MAPK) phosphorylation (figure 6A y B and Figure
S6), in accordance with our data on the effects of CPMZ/MCD on
IGF1R signaling (figure 2C and D). AKT phosphorylation elicited
a reduction of around 50% when treated with AEW, and 35–40%
when treated with CPMZ/MCD. The triple combination almost
completely abolished AKT phosphorylation. Regarding MAPK,
its phosphorylation was only reduced with AEW or CPMZ
treatment (45 and 65% reduction, respectively), undergoing a
higher reduction with the AEW+CPMZ combination. This
suggests that CAV1 internalization probably does not mediate
MAPK signaling.
In this study we detected changes in the phosphorylation of
several other proteins (figure 6C), such as p38, TOR, MEK1/2,
among others. Interestingly, 37% of all proteins underwent the
strongest reduction in phosphorylation with CPMZ or MCD
treatment and only 10% did so with AEW, while 24% underwent
the highest reduction in phosphorylation with the triple treatment.
These results suggest that AEW alone is able to inhibit IGF1R
signaling but that this process may be enhanced by the
combination with endocytosis inhibitors such as CPMZ and/or
MCD.
Discussion
It has been described that IGF1R upregulation promotes cell
survival and proliferation in many types of cancer, including
carcinomas such as prostate [15], breast [16] and lung carcinomas
[17,18], and also in sarcomas [11,19]. Moreover, IGF1R plays an
important role in the transformation, motility and metastasis of
IGF1R Endocytosis in Ewing Sarcoma
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19846Figure 1. Confocal microscopy studies of IGF1R internalization in TC71 cells by Cav1-and clathrin-dependent mechanisms. Ewing’s
sarcoma TC71 cells were treated as described in the Material and Methods section. A) Cav1-dependent endocytosis studies. B) Clathrin-dependent
endocytosis studies. Under basal conditions (non-stimulated with IGF1, see ‘control’ rows), IGF1R is confined to the membrane surface, while after
IGF1 treatment it is internalized by clathrin- and caveolin1-dependent mechanisms, thus co-localizing with both clathrin/Cav1 inside the endocytic
vesicles (see asterisks). The far right side panels show high magnifications for merge images. The bottom panels show additional images for IGF1R
localization in the cytoplasm after IGF1-driven internalization. After ligand stimulation, IGF1R localizes both in ES cells membrane and cytoplasm, co-
localizing with clathrin within the clathrin-coated pits (see arrows). The results obtained with CAV1 were similar to those shown for clathrin (data not
shown). Scale bars represent 10–20 mm, left and right hand panels, respectively. Data presented is representative of 4–6 independent experiments.
doi:10.1371/journal.pone.0019846.g001
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therapy [22,23]. Currently, there are 12 anti-IGF1R strategies
undergoing clinical evaluation, including monoclonal antibodies
and small-molecule tyrosine kinase inhibitors [22,24]. Nonetheless,
we believe that the full mechanism of IGF1R signalling remains to
be clarified.
IGF1R is able to activate several signalling pathways through
the phosphorylation of different intracellular proteins, including
insulin receptor substrate-1 (IRS-1) and the Shc proteins
[25,26,27], among many others. Several studies have previously
shown that following hormone binding, IGF1R is internalized
through endocytosis [28,29], culminating in the formation of early
endosomes containing the internalized active receptor [30,31].
Also, Baserga et al. [32], demonstrated a strict correlation between
the protein levels of CAV1 and IRS-1 in mouse embryo fibroblasts
(MEFs) following deletion of the CAV1 gene (KO cells), where
they found that IRS-1 was also downregulated. Recently, Sehat
et al., confirmed this hypothesis in an osteosarcoma model [9],
demonstrating that IGF1R undergoes ligand-dependent internal-
ization through both clathrin-coated vesicles and caveolae. Thus,
in this model the ligand concentration determines the trafficking
pathway (caveolin-dependent or clathrin-dependent).
In line with this, we decided to study the involvement of IGF1R
internalization in ES signaling and its possible targeting benefits.
Initially, we observed that IGF1R was being internalized in ES cell
lines after ligand binding, mainly due to clathrin–dependent
mechanisms. We were able to show that i) clathrin or CAV1
inhibition/interference blocks IGF1R internalization, ii) IGF1R
signaling in ES largely depends on receptor internalization, and iii)
the pro-survival and anti-apoptotic effects of IGF1R signaling are
considerably reduced when internalization is blocked.
The results obtained support the initial hypothesis to the effect
that IGF1R signaling is enhanced after receptor internalization in
ES. This mechanism allows access of upstream active kinases to
direct downstream targets, thus permitting higher signaling
specificity through the different subcellular compartments. Based
Figure 2. IGF1R internalization in TC71 cells by clathrin- and Cav1-dependent mechanisms and the effects of CAV1 or clathrin
inhibition/interference in the IGF1R signaling pathway. A) Studies of RCM/EM microscopy show IGF1R in the ES cell cytoplasm (top panel,
white arrows) and in the vesicles budding off the cell membrane (bottom picture, black arrows) after ligand binding. Scale bar represents 1 (RCM) or
0.1 mM (EM). B) IP/WB studies show that after stimulation with ligand (3rd, 5th and 7th lane), IGF1R co-precipitates with both clathrin (1
st row 5th
lane; 2
nd row 3
rd lane) and with Cav1, although to a lesser extent (1
st row 7th lane, 3
rd row 3
rd lane). TE: total extract. C) WB detection of the IGF1R
signaling pathway after CAV1 or D) clathrin interference/inhibition. Both approaches inhibited the IGF1R signaling pathway, inhibiting both AKT and
MAPK42/44 phosphorylation. Data presented is representative of 3–5 independent experiments for the RCM/EM studies and 3–6 independent
experiments for the IP/WB studies.
doi:10.1371/journal.pone.0019846.g002
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19846on our results, we propose that in ES, after ligand binding, IGF1R
is internalized under two different mechanisms: i) one dependent
on clathrin and ii) the other caveolin-dependent (figure 7).
However, it was predictable that IGF1R would be internalized
by clathrin-dependent mechanisms, since this mechanism had
already been reported for several RTKs, including IGF1R, in
Figure 3. Confocal microscopy studies of IGF1R internalization after CAV1 or clathrin interference A)/inhibition B). Ewing’s sarcoma
TC71 cells were treated as described in the Material and Methods section. In comparison to control conditions (see figure 1), in the interfered/
inhibited conditions IGF1R remains retained in the membrane after ligand stimulation. Scale bar represents 20 mm. Data presented is representative
of 4–6 independent experiments.
doi:10.1371/journal.pone.0019846.g003
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internalization through caveolin-dependent mechanisms clearly
confirms previously published data [9] and provides new insight
into the regulation of RTKs throughout internalization in ES.
Moreover, Notario’s group has recently shown that CAV1 is a
target of EWS/FLI1 and that it is determinant for the oncogenic
phenotype and tumorigenicity of ES cells. In fact, this particular
study [33] shows that CAV1 knockdown reduces the growth of ES
cell-derived tumors in nude mice xenografts. Also in that study the
reactivation of CAV1 expression in ES cells enabled the rescue of
the original oncogenic phenotype. Furthermore, Toretsky’s data
[34] showed that IGF1R is required for the EWS/FLI-1
transformation of fibroblasts.
Taken together, all these findings lead to the hypothesis that
these molecular hits could be promoting ES tumorigenicity. Our
results suggest that IGF1R internalization in ES is under a highly
controlled spatial and temporal regulation, combining both
clathrin and CAV1 mechanisms and underscoring the role of
CAV1 in RTK endocytosis.
In keeping with the observations discussed previously, together
with Podar’s studies in multiple myeloma [35] and our results from
the phospho-array assay, we suggest that IGF1R clathrin-
Figure 4. Effects of CAV1 or clathrin inhibition/interference in ES cell line proliferation and apoptosis. A) CAV1 or clathrin inhibition
reduced ES cell line proliferation in a dose-dependent manner with an IC50 of proliferation similar in all ES cell lines tested (between 10–15 mM for
CPMZ and 4–4.5 mM for MCD). B) The results obtained regarding the induction of apoptosis were similar to those obtained with the inhibition of
proliferation in all cell lines (A673 and A4573 data shown in SD figure S3). A/N: Apoptotic and Necrotic cells. C) CAV1 or clathrin siRNAs induced
around 40% of the inhibition of proliferation and 40–45% of apoptosis induction. Data presented as the average of 4–6 independent replicates.
doi:10.1371/journal.pone.0019846.g004
IGF1R Endocytosis in Ewing Sarcoma
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19846endocytosis mainly regulates the RAS/RAF/MEK/ERK path-
way in ES. Moreover, we believe that endocytosis further improves
the IRS1/PI3K/AKT signaling pathway, since CPMZ treatment
also reduced AKT, TOR and p70S6K phosphorylation. None-
theless, we assume that the PI3K/AKT pathway undergoes its
strongest activation either directly from the membrane, with IRS1
activation independent of IGF1R internalization (like the one
reported by Chow et al.,[36]) or with an extra regulation, through
caveolin-dependent internalization [13]. The data supporting this
assumption show that the phosphorylation of AKT is already
reduced by about 50% with AEW treatment (confirming that
IGF1R signaling pathway activation is not totally dependent upon
internalization), even though it showed a large improvement with
the triple treatment, 80% of inhibition being reached. More
importantly, the residues whose phosphorylation is reduced in the
AKT, TOR, AMPK and p70S6K proteins are different,
depending on the treatment used (CPMZ vs MCD vs combina-
tion). This constitutes additional evidence that endocytosis not
only provides additional control over the ‘‘quantity’’ of RTKs
signaling, but also over the ‘‘quality and selectivity’’ of such
signaling. The model suggested here (see figure 7) provides new
insight into the selectivity and specificity of IGF1R signaling
driven from different cellular compartments.
With the studies on the effects of AEW541 and the CPMZ/
MCD combination on ES cells, here we demonstrate that IGF1R
tyrosine kinase inhibition is improved when combined with CAV1
or clathrin inhibition, reducing the levels of proliferation and the
induction of apoptosis in ES cell lines. The effects of the drug
combination had an impact on the phosphorylation status of
several proteins, namely AKT, SRC p38, TOR, MSK1/2,
MEK1/2, among others, confirming once again that IGF1R
signaling depends on its internalization. Also, proteins such as
HSP27, AKT, b-catenin, AMPKa and STAT2/4/3 exhibited the
highest reduction in phosphorylation with the triple treatment,
supporting the idea of combining TK inhibitors with internaliza-
tion blockers in order to decrease signaling. It should be noted that
RTK-blocking antibodies would, in theory, only block receptors
located in the cellular membrane, not affecting the receptors
already internalized. In this case, the small-molecule tyrosine
kinase inhibitors would be a better choice since they would diffuse
to the cytoplasm and also inhibit some of the receptors within the
endocytic vesicles.
Figure 5. Effects of IGF1R tyrosine kinase inhibition combined with CAV1 or clathrin inhibition on ES cell proliferation and
apoptosis. A) Isobolograms of AEW combined with MCD/CPMZ. B) Combination index (CI) of AEW combined with MCD/CPMZ. AEW combined with
MCD shows additive effects in the inhibition of ES cell line proliferation (CI around 1). In contrast, regarding AEW combined with CPMZ the effects
were synergistic (CI between 0.73–0.86) in the A4573 and TC71 cell lines, and only additive in the A673 cell line. C) AEW combined with MCD/CPMZ
had additive effects on the induction of apoptosis in ES cell lines, mainly inducing late apoptosis, with few cells undergoing necrosis. A: AEW, C: CPMZ
and M: MCD. Data presented as the average of 4–6 independent replicates.
doi:10.1371/journal.pone.0019846.g005
IGF1R Endocytosis in Ewing Sarcoma
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19846In conclusion, here we show that blockade of IGF1R
internalization, either by clathrin or caveolin1, inhibits IGF1R
signalling in ES cells. Accordingly, we provide new evidence
regarding the role of cav1/clathrin endocytosis in IGF1R
internalization. Finally, we consider the combination of TK
inhibitors with endocytosis inhibitors as a major and plau-
sible strategy to reduce ES cell proliferation through IGF1R
signaling.
The results shown here are focused on Ewing Sarcoma, but it is
extremely likely that they may find a more general application in
sarcomas, and in several subsets of other more prevalent
neoplasms that depend largely upon IGF1R survival signals (i.e.
subsets of lung or breast carcinoma), therefore increasing the
potential impact of our findings for sarcoma therapy.
Materials and Methods
Cell lines
The A673, TC-71, SK-ES-1, A4573 and TTC466 cell lines
were obtained and maintained as previously described [11,12,37].
All cells were free of Mycoplasma, as screened with the MycoAlert
Mycoplasma Detection kit (Lonza, Rockland, ME).
Drugs
AEW541 (AEW) was kindly provided by Novartis Pharma AG,
Basel, Switzerland. Chlorpromazine (CPMZ) and Methyl-b-
cyclodextrin (MCD) were purchased from Sigma-Aldrich (St
Louis, MO).
siRNA
Caveolin1 pre-designed siRNA, clathrin-validated siRNAs and
Silencer negative control siRNA were purchased from Ambion
(Austin, TX). Cell lines were treated with 100 nM siRNAs, as
previously described,[12] using lipofectamine 2000 (Invitrogen,
Carlsbad, CA), according to the manufacturer’s instructions.
Immunofluorescence (IF) and Confocal Microscopy (CM)
Cells were grown overnight on sterile glass slides (covered with
gelatine 0.1%), with serum-free medium and then stimulated with
IGF1 for 15 minutes. The glass slides were washed with PBS and
Figure 6. Effects of IGF1R tyrosine kinase inhibition combined with CAV1 and/or clathrin inhibition on the ES cell phospho-
proteome. A) AKT and MAPK42/44 protein levels and B) densitometric evaluation. The reduction in the phosphorylation of AKT and MAPK42/44 was
over 60%. C) Graphic representation of the most relevant changes in protein phosphorylation. Some of them underwent the strongest reduction in
phosphorylation simply with CPMZ/MCD treatment (p38, ERK1/2, MEK1/2, or TOR). However, others needed the triple combination in order for the
lowest levels of activation to be obtained (such as AKT, HSP27, or AMPKa1). A: AEW, C: CPMZ and M: MCD treatments; + control: IGF1 stimulation
without drug treatment; - control: basal conditions, without IGF1 stimulation. Data presented is representative of 3–5 independent experiments for
the WB studies and 3 independent experiments for the phospho kinase array.
doi:10.1371/journal.pone.0019846.g006
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Cells were permeabilized in PBS/Triton x-100 0,1% (Invitrogen)
for 30 minutes, incubated with PBS 50 nM NH4CL for 10
minutes, blocked for 30 minutes with PBS 0.2% BSA (Sigma
Aldrich), and incubated overnight at 4uC with one of the
following primary antibodies; rabbit polyclonal antibody against
caveolin1 (Abcam), or rabbit polyclonal antibody against clathrin
(Abcam), or mouse monoclonal antibody against clathrin (Affinity
Bioreagents). After three washes in PBS, the slides were incubated
with one of the following secondary antibodies: chicken anti-
rabbit AlexaFluor594 (Invitrogen) or goat anti-rabbit Cy3
(Jackson ImmunoResearch Laboratories, Inc, West Grove, PA)
or goat anti-mouse AlexaFluor594 (Invitrogen), for 45 min, and
washed three times. Then, all the slides were incubated with
rabbit polyclonal antibody against IGF1R (cell signalling) for
1 hour, washed three times, and incubated with chicken anti-
rabbit Alexa 488 (Invitrogen) for 1 hour. Following this, cells
were washed three times and nuclear DNA was counterstained
with DAPI (2.5 mg/mL) (Invitrogen). Cells were mounted using
the Slowfade Gold Antifade reagent (Invitrogen) or Vectashield
H-1000 medium (Vector). A Zeiss LSM510 confocal microscope
or a Leica inverted fluorescence microscope connected to a
digital video camera (Leica DC100) were used to obtain confocal
or fluorescence images. Confocal image analysis was performed
using the LSM 5 Image Browser (program version 2.8). 4–6
independent experiments were performed and the final data
presented selected as the most representative of the results
obtained.
Immuno-Electron (EM) and Reflection Contrast
Microscopy (RCM)
After treatment with IGF1, cells were fixed for 15 minutes in
2% paraformaldehyde/0.1% glutaraldehyde and spun down at
7500 rpm for 5 min. Cells were embedded in 12% gelatine, spun
Figure 7. Simplified model for IGF1R signaling in ES. Globally, after ligand binding IGF1R can signal directly from the membrane (IGF1R
signaling internalization-independent), with a major degree of IRS1/PI3K/AKT signaling activation and a smaller enhancement of the Ras/Raf/MEK/ERK
signaling pathway, or, when internalized either by clathrin and/or caveolin-dependent mechanisms, it can signal from vesicles. In the case of clathrin-
dependent endocytosis, IGF1R is recruited to CCPs through interaction of its cytoplasmic tails with the protein adaptor AP2, which in turn recruits
clathrin to the plasma membrane and promotes its assembly into a lattice network. Through protein-protein interaction, clathrin and AP2 also bind
several proteins of the endocytic machinery, such as dynamin, which regulates the fission of the CCPs with the consequent formation of CCVs, and
GRB2, which recruits and binds the SOS protein and the IGF1R-phosphorylated protein Shc, activating the RAS/RAF/MEK/ERK and p38MAPK signaling
pathways. To a lesser extent, it also activates the IRS1/PI3K/AKT signaling pathway. In the case of caveolin-dependent endocytosis, IGF1R is recruited
to caveolae, promoting caveolin phosphorylation and the subsequent recruitment of dynamin, which promotes caveolar budding and the formation
of cavicles. Cav-1 phosphorylation phosphorylates IRS-1, enhancing the activation of thePI3K/AKT signaling pathway. The thickness of the arrows
indicates the prevalence of signaling pathway activation. CPMZ treatment inhibits the formation of CCP by inhibiting clathrin-heavy-chain
conformations and MCB inhibits the formation of cavicles by depleting cholesterol, disrupting the caveolae.
doi:10.1371/journal.pone.0019846.g007
IGF1R Endocytosis in Ewing Sarcoma
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on top of them). Cell pellets were cut on an ultramicrotome (Leica,
Germany) at 70 nm thickness and sections were placed on carbon-
coated hexagonal grids. The sections were incubated with rabbit
polyclonal antibody against IGF1R overnight at 4uC, washed with
PBS, incubated with ProteinA-Gold-10 nm antibody for 2 h at
room temperature, and embedded in methyl-cellulose-0.3%
uranyl acetate for 5 min. Photos were taken with a JEOL
JEM1011 Transmission Electron Microscope connected to a
digital video camera (MegaView III) or a Leica DM/RB
microscope with an RCM module and a DFC-420C digital
camera. 3–5 independent experiments were performed and the
final data presented selected as the most representative of the
results obtained.
Western Blotting (WB) and Immunoprecipitation (IP)
IP and WB studies were performed as previously reported
[11,12]. The antibodies used were: anti-AKT, anti-p-AKT
(Ser473), anti-MAPK42/44, anti-p-MAPK42/44 (Thr202/
Tyr204) (all from Cell Signaling, Danvers CA), anti-caveolin1
(Abcam), anti-clathrin (Affinity Bioreagents) and anti-GAPDH
(Abcam). 3–6 independent experiments were performed and the
final data presented selected as the most representative of the
results obtained.
Proliferation studies
The dose-response proliferation levels of the cell lines subjected
to drug treatment were analyzed to determine the IC50 of
proliferation (control treatment performed using the vehicle for
CPMZ and MCD). The percentage of proliferation inhibition
induced by the specific CAV1/clathrin siRNAs was also evaluated.
4–6 independent experiments were performed and the final data
are presented as averages of all replicates. To determine the
proliferation rate, we used the MTT method, as previously
described.[11]
Apoptosis
The apoptosis and necrosis indices were assessed by flow
cytometry, as previously described.[11] 3–5 independent experi-
ments were performed, the final data being presented as averages
of all replicates. Briefly, cell pellets were washed twice with PBS
and stained with Anexin V for 15 minutes, washed, and then
stained with Propidium Iodide (IP) for 5 minutes. Cells were
acquired in a FACS Calibur cytometer. Cells with doble staining
were considered as Apoptotic and Necrotic (A/N) while cells with
no staining were considered Alive. 4–6 independent experiments
were performed and the final data are presented as averages of all
replicates.
Isobolographic Analysis
The effects of the combination of AEW with CPMZ or MCD
were analyzed using Loewe’s isobolographic analysis, revised by
Steel and Peckman, as previously described [11]. Briefly, for
isoeffective doses of a two-drug combination (dA + dB) and the
individual drugs alone (DA and DB), combinations having a
combination index (CI).1 were considered antagonistic; those
with a combination index=1 were additive, and those with a
combination index ,1 were synergistic, the combination index
being = dA/DA + dB/DB. The CI values for each condition
were calculated using the IC50 of proliferation as the isoeffective
point (using Origin 6.0 to plot the data). Isobolograms were
acquired by plotting the IC50 of AEW on the Y-axis and the IC50
of CPMZ or MCD on the X-axis.
Phospho-kinase array
The effects of the AEW with CPMZ and/or MCD combina-
tions were analyzed at the level of global kinase phosphorylation,
using the dot-blot Proteome Profiler
TM Array Human Phospho-
Kinase Array Kit (R&D Systems), according to manufacturer’s
instructions. Briefly, cells were treated with 75 nM AEW, 7.5 mM
CPMZ and/or 2.5 mM MCD for 1 hour, stimulated with IGF1
for 15 minutes, and lysates were prepared with the appropriate
lysis buffer (PBS 1x, 1 mM Na2EDTA, 1 mM EGTA, 50 mM
NaF, 1%Triton x-100, 5 mM Na3VO4 and protease inhibitor
cocktail tablet (Roche). 400 mg of protein was used. The signals
from the membranes were detected as described for WB and the
levels of chemiluminescence of each spot were evaluated by 2D-
densitometry using the AIDA
. software (Fujifilm-Raytest,
Straubenhardt, Germany). 3 independent experiments were
performed and the final data are presented as averages of all
replicates.
Statistical Analyses
One-Way ANOVA for independent samples was performed,
using the VassarStats web site for Statistical Computation.
Supporting Information
Figure S1 siRNA knockdown efficiency studies. Ewing’s
sarcoma cells were grown until they reached 30–40% confluence,
treated with CAV1 or clathrin siRNAs, and then proteins were
extracted and WB performed, as described in the Materials and
Methods section. A) WB detection of clathrin and Cav1 protein
levels. B) Densitometric analysis of the WBs. The siRNAs used
effectively reduced CAV1/clathrin protein levels, with a 40–65%
reduction, depending on the ES cell line treated. UTF:
untransfected; mock: transfected without siRNA. 3 independent
experiments were performed and the final data presented selected
as the most representative of the results obtained -panel A and as
averages of all replicates-panel B.
(TIF)
Figure S2 Densitometric analyses of WB shown in
figure 2C and D of effects of CAV1 or clathrin
inhibition/interference on the IGF1R signaling pathway.
The inhibition of phosphorylation reached levels of over 60%
reduction (p,0.05). The results obtained with the A673 and A4573
cell lines were identical to those described for TC71 (data not shown).
Data presented is representative of 3–6 independent experiments.
(TIF)
Figure S3 Effects of CAV1 or clathrin inhibition/
interference on the IGF1R signaling pathway. Ewing’s
sarcoma TC71 cells were starved overnight, stimulated with IGF1
(50 ng/ml) for 15 minutes, and then proteins were extracted and
WB was performed, as described in the Material and Methods
section. A) Effects of clathrin inhibition/interference. B) Effects of
Cav1 inhibition/interference. The phosphorylation of AKT and
MAPK proteins in siRNA- or drug-treated cells without IGF1
treatment showed that siRNA or drug treatment alone do not
interfere with protein phosphorylation. 3 independent experiments
were performed and the final data presented selected as the most
representative of the results obtained.
(TIF)
Figure S4 Effects of CAV1 or clathrin inhibition on
apoptosis in the ES cell lines A673 and A4573. Ewing’s
sarcoma cells were grown until they reached 30–40% confluence,
treated with MCD/CPMZ for 72 hours, and then apoptosis was
measured by flow cytometry, as described in the Materials and
IGF1R Endocytosis in Ewing Sarcoma
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19846Methods section. Drug treatment induced apoptosis in a dose-
dependent manner in all ES cell lines, mainly inducing late
apoptosis, with few cells undergoing necrosis. Data presented as
the average of 4–6 independent replicates.
(TIF)
Figure S5 Effects of CAV1 or clathrin inhibition on an
IGF-1-independent ES cell line. Ewing’s sarcoma TTC466 cells
were grown until they reached 30–40% confluence, treated with
MCD/CPMZ for 72 hours, and then proliferation was measured
with the MTT assay, as described in the Materials and Methods
section. A) Characterization of the IGF1 proliferation-driven
signaling dependence of the TTC466 cell line, as already published
by Martins el al. Cancer Res. 2008; 68(15):6260–70. B) CPMZ or
MCD treatment. CAV1 or clathrin inhibition hardly affected ES cell
line proliferation. The IC50 of proliferation was much higher than
with the 3 other cell lines studied (5–10x), showing that the toxicity of
CPMZ and MCD is related to IGF1R endocytosis inhibition and not
due to non-specific secondaryeffects of thesedrugs. Data presented as
the average of 4-6 independent replicates.
(TIF)
Figure S6 Effects of IGF1R tyrosine kinase inhibition
combined with CAV1 and/or clathrin inhibition on the
ES cell phospho-proteome. Images of the p-array membranes
of all samples studied. A: AEW, C: CPMZ and M: MCD
treatments; + control: IGF1 stimulation without drug treatment;
- control: basal conditions, without IGF1 stimulation. Data
presented is representative of 3 independent experiments.
(TIF)
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